Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.
Bevacizumab and tranexamic acid have shown efficacy in the treatment of epistaxis and liver involvement of HHT patients. We suggest therapeutic association of bevacizumab and tranexamic acid should be further evaluated for the prevention and treatment of early lung involvement in HHT.